Survival prognosis in advanced HER-2 negative gastric cancer treated with immunochemotherapy: A novel model

Table 4 Univariate and multivariate analyses of prognostic factors for overall survival

Factors	Univariate		Multivariate
	HR (95%CI)	P value	HR (95%CI)	P value
Sex (female vs male)	1.10 (0.68-1.77)	0.704
Age (< 60 vs ≥ 60), years	0.90 (0.57-1.43)	0.663
BMI (≥ 25 vs < 25), kg/m2	1.17 (0.66-2.06)	0.586
CEA (< 3 vs ≥ 3), ng/mL	1.39 (0.88-2.20)	0.152
CA199 (< 37 vs ≥ 37), U/mL	1.43 (0.89-2.27)	0.136
ECOG PS (0 vs 1)	1.63 (0.98-2.71)	0.059
Staging (3 vs 4)	4.12 (2.38-7.13)	< 0.001	3.73 (2.05-6.81)	< 0.001
Differentiation (low vs medium-high)	0.13 (0.03-0.54)	0.005	0.18 (0.04-0.74)	0.018
Site (stomach vs gastric and esophageal binding)	1.30 (0.77-2.18)	0.326
Liver metastasis (no vs yes)	1.58 (0.96-2.61)	0.072
Peritoneal metastasis (no vs yes)	1.41 (0.90-2.22)	0.136
PD-L1 expression (CPS < 5 vs CPS ≥ 5)	0.18 (0.11-0.31)	< 0.001	0.45 (0.26-0.76)	0.003
MMR status (dMMR vs pMMR)	0.10 (0.03-0.32)	< 0.001	0.20 (0.06-0.73)	0.015
EBV status (infect vs no-infect)	0.57 (0.21-1.57)	0.279
CALLY index	0.86 (0.79-0.92)	< 0.001	0.88 (0.81-0.95)	0.002
NLR	1.18 (1.11-1.26)	< 0.001	1.16 (1.08-1.25)	< 0.001
SII	1.04 (0.97-1.11)	0.275

BMI: Body mass index; CEA: Carcinoembryonic antigen; CA199: Carbohydrate antigen 199; ECOG PS: Eastern Cooperative Oncology Group performance status; PD-L1: Programmed cell death ligand 1; CPS: Combined positive score; MMR: Mismatch repair; dMMR: Deficient mismatch repair; pMMR: Proficient mismatch repair; EBV: Epstein-Barr virus; CALLY: C-reactive protein-albumin-lymphocyte; NLR: Neutrophil-to-lymphocyte ratio; SII: Systemic immune inflammation.